GENE ONLINE|News &
Biodexa Pharmaceuticals Partners with Syngene International for GMP Production of MTX240 Clinical Trial Supplies
Biodexa Pharmaceuticals has entered into a partnership with Syngene International Limited to produce GMP clinical trial supplies for MTX240, a drug candidate currently under development. The collaboration aims to support the manufacturing needs of MTX240 as it progresses through clinical trials.
Under the agreement, Syngene will handle the production of MTX240 in compliance with Good Manufacturing Practices (GMP) standards. This ensures that the drug meets regulatory requirements for quality and safety during its clinical evaluation phase. Biodexa is advancing MTX240 as part of its pipeline, and this partnership marks a key step in preparing for upcoming trials. Further details regarding timelines or specific trial phases were not disclosed at this time.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: April 2, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Study Finds Non-Communicable Diseases Consume Large Portion of Household Income Among Elderly in India
2026-04-19
Study Identifies Antiviral Compounds in Egyptian Ziziphus spina-christi Effective Against Respiratory Viruses
2026-04-19
Elevated Fetal Catecholamine Metabolites Linked to Growth Restriction in Sheep Model Study
2026-04-18
EVENT
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
